AEMD

Aethlon Medical Inc. 10-K Summary (Fiscal Year Ended March 31, 2010)

Business Context and Reporting Period

Aethlon Medical, Inc. is a development-stage medical device company focused on the Hemopurifier(R), a platform technology designed to selectively remove infectious viruses and immunosuppressive proteins (exosomes) from the circulatory system. The company targets therapeutic applications in cancer, Hepatitis-C (HCV), HIV, and bioterrorism/pandemic threats. The reporting period covers the fiscal year ended March 31, 2010. The company has no revenue from product sales and relies on financing to fund research and development.

Key Financial Metrics

Note: The company recorded a gain of $178,723 from the change in fair value of derivative liabilities in 2010, offsetting some losses.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $1.5 million compared to the prior year, primarily due to a reduction in payroll expenses ($368,007 decrease) and lower amortization of note discounts.
• Derivative Liabilities: Due to the adoption of new accounting guidance (ASC 815-40) effective April 1, 2009, the company reclassified certain embedded conversion features of convertible debt as derivative liabilities. This resulted in a $1,054,716 liability on the balance sheet at March 31, 2010, which did not exist in the prior period.
• Debt Settlement: The company recognized a $341,984 loss on the settlement of accrued interest and damages in 2010, compared to a $1.6 million loss on extinguishment of debt in 2009.
• Professional Fees: Increased by $238,917, largely driven by costs associated with establishing Good Manufacturing Practice (GMP) manufacturing and business development activities.

Outlook, Risks, and Management Commentary

• Going Concern: The company's independent auditors have issued an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. Management states that significant additional capital is required to advance product development to commercial viability.
• Liquidity: Cash on hand ($67,950) plus funds raised subsequent to year-end ($358,600) are insufficient to meet funding requirements for the next twelve months. The company must obtain additional financing to continue operations.
• Regulatory Status: The Hemopurifier(R) is not yet approved by the FDA for human use. The company plans to initialize commercialization in India while advancing clinical strategies in the U.S. and EU. An Investigational Device Exemption (IDE) has been submitted to the FDA.
• Internal Controls: Management identified material weaknesses in internal control over financial reporting, specifically regarding segregation of duties in cash disbursements and a lack of sufficient accounting personnel.
• Intellectual Property: Patents comprise a significant portion of the company's assets (22% of total assets). The company relies on third-party licenses for cancer-related applications, which poses a risk if terminated.

Key Facts for Investor Verification

• Zero Revenue: Verify the company's ability to generate revenue given it has no history of profitable operations and no product sales to date.
• Financing Needs: Confirm the status of ongoing capital raising efforts, as the company explicitly states it cannot continue operations without additional financing.
• Debt Structure: Review the terms of outstanding convertible notes, many of which are past due or in default, and the associated derivative liabilities that impact net loss.
• Regulatory Milestones: Monitor progress on FDA IDE approvals and the status of clinical trials in India and the U.S., as commercialization is entirely dependent on regulatory clearance.
• Dilution Risk: Note the large number of outstanding options, warrants, and convertible notes (over 38 million shares underlying options/warrants and 14 million underlying convertible notes) which could result in significant dilution.